FIGURE 6.

Effect of WOBE437 on allodynia and inflammation after a single dose or 3 days treatment in a mouse model of monoarthritis. (A) Treatment scheme of monoarthritis induced by knee immunization with complete Freund’s adjuvant (CFA) (40 μL, intra-articular) in which the inflammatory process was allowed to develop for 14 days. Intraperitoneal treatments with WOBE437 were carried on days 15 to 17. (B) Allodynia was evaluated upon single dose treatments in which 10 mg/kg of WOBE437 increased the pain threshold. After 3 days of treatment, 10 mg/kg of WOBE437 improved (C) allodynia and reduced (D) edema. (E) The development of monoarthritis significantly decreased the travel distance in the open field test, but no significant changes were observed after WOBE437 treatment due to high variability. Indomethacin was used as a reference drug. All doses are shown in mg/kg, i.p. Allodynia was evaluated by mechanical sensitivity and edema through knee diameter and both were measured 1 h after pharmacological treatments. All data show mean values ± SD of at least 6 to 15 mice. Groups were compared using Kruskal–Wallis test followed by Mann–Whitney test. ^∗p < 0.05 vs. ipsilateral/vehicle; ^#p < 0.05 vs. contralateral/healthy; i.p., intraperitoneally.